<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00348400</url>
  </required_header>
  <id_info>
    <org_study_id>5099</org_study_id>
    <nct_id>NCT00348400</nct_id>
  </id_info>
  <brief_title>Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost</brief_title>
  <official_title>Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovative Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovative Medical</source>
  <brief_summary>
    <textblock>
      Evaluate the relative efficacy and tolerability of Alphagan P compared to Trusopt as
      adjunctive therapy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single</masking>
  </study_design_info>
  <condition>Glaucoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  · Male or female &gt; 18 years of age

               -  Diagnosis of open-angle glaucoma or ocular hypertension

               -  IOP &gt; 16 mm Hg in each eye at the latanoprost -treated baseline evaluation

               -  Presently on latanoprost monotherapy for at least 6 weeks

               -  Ability to provide informed consent and likely to complete all study visits

        Exclusion Criteria:

          -  · Known contraindication or allergy to brimonidine or any of its components

               -  Subjects must be naive to brimonidine 0.2% or brimonidine Purite 0.15% and
                  dorzolamide 2%

               -  Uncontrolled systemic disease

               -  Active ocular disease other than glaucoma or ocular hypertension (e.g. uveitis,
                  ocular infections, or severe dry eye). Patients with chronic mild blepharitis,
                  cataract, age-related macular degeneration, or background diabetic retinopathy
                  may be enrolled at the discretion of the investigator.

               -  Required use of ocular medications other than the study medications during the
                  study (intermittent use of artificial tear product is allowed).

               -  Corneal abnormalities

               -  History of intraocular surgery within the last 3 months

               -  Female patients of childbearing potential who are pregnant, lactating, planning a
                  pregnancy, or not using a reliable form of birth control

               -  Visual field loss, which in the opinion of the investigator, is functionally
                  significant, or evidence of progressive visual field loss within the last year.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Robert Noecker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UPMC Eye Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Noecker</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2006</study_first_submitted>
  <study_first_submitted_qc>June 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2006</study_first_posted>
  <last_update_submitted>May 30, 2007</last_update_submitted>
  <last_update_submitted_qc>May 30, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2007</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
    <mesh_term>Dorzolamide</mesh_term>
    <mesh_term>Brimonidine Tartrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

